Ocular Manifestations of Inherited Diseases Maya Eibschitz-Tsimhoni
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Dermatology Eponyms – Sign –Lexicon (P)
2XU'HUPDWRORJ\2QOLQH Historical Article Dermatology Eponyms – sign –Lexicon (P)� Part 2 Piotr Brzezin´ ski1,2, Masaru Tanaka3, Husein Husein-ElAhmed4, Marco Castori5, Fatou Barro/Traoré6, Satish Kashiram Punshi7, Anca Chiriac8,9 1Department of Dermatology, 6th Military Support Unit, Ustka, Poland, 2Institute of Biology and Environmental Protection, Department of Cosmetology, Pomeranian Academy, Slupsk, Poland, 3Department of Dermatology, Tokyo Women’s Medical University Medical Center East, Tokyo, Japan, 4Department of Dermatology, San Cecilio University Hospital, Granada, Spain, 5Medical Genetics, Department of Experimental Medicine, Sapienza - University of Rome, San Camillo-Forlanini Hospital, Rome, Italy, 6Department of Dermatology-Venerology, Yalgado Ouédraogo Teaching Hospital Center (CHU-YO), Ouagadougou, Burkina Faso, 7Consultant in Skin Dieseases, VD, Leprosy & Leucoderma, Rajkamal Chowk, Amravati – 444 601, India, 8Department of Dermatology, Nicolina Medical Center, Iasi, Romania, 9Department of Dermato-Physiology, Apollonia University Iasi, Strada Muzicii nr 2, Iasi-700399, Romania Corresponding author: Piotr Brzezin′ski, MD PhD, E-mail: [email protected] ABSTRACT Eponyms are used almost daily in the clinical practice of dermatology. And yet, information about the person behind the eponyms is difficult to find. Indeed, who is? What is this person’s nationality? Is this person alive or dead? How can one find the paper in which this person first described the disease? Eponyms are used to describe not only disease, but also clinical signs, surgical procedures, staining techniques, pharmacological formulations, and even pieces of equipment. In this article we present the symptoms starting with (P) and other. The symptoms and their synonyms, and those who have described this symptom or phenomenon. Key words: Eponyms; Skin diseases; Sign; Phenomenon Port-Light Nose sign or tylosis palmoplantaris is widely related with the onset of squamous cell carcinoma of the esophagus. -
Cone Interaction with Progressive Macular Dysfunction
Correspondence 823 Sir, occasionally in the context of ectodermal dysplasia Management of ankyloblepharon filiforme adnatum syndromes3 and popliteal pterygium syndrome.4 AFA has also been reported in association with Edward’s Ankyloblepharon filiforme adnatum (AFA) is a syndrome,5 and CHANDS6 (curly hair, ankyloblepharon, rare congenital malformation affecting the eyelids. nail dysplasia). Other associations include hydrocephalus, We report a case describing its management. meningomyelocoele, and imperforate anus,7 cardiac defects and syndactyly.4 Detailed systemic assessment by an experienced paediatrician is therefore imperative in Case report the management of AFA. Our report illustrates a simple surgical approach that A male neonate was referred for assessment of his left is modified from previously published cases.1,2,4 It is safe eyelids. He was born at term, to a primigravid mother, and well tolerated with the aid of topical anaesthesia. weighing 3150 g. Pregnancy and delivery were Surgical correction should be performed promptly to unremarkable. There was no family history of minimise any risk of occlusion amblyopia, and enable ophthalmic or systemic disease. A detailed systemic full examination of the eye. assessment by a paediatrician was clear. Ocular examination showed partial fusion of his left upper and lower eyelids by a central, narrow band Conflict of interest of tissue, arising from the grey lines (Figure 1). Full The authors declare no conflict of interest. eyelid opening was impaired and interpalpebral aperture was limited to 3.5 mm. Right eye examination was normal. The band of tissue was retracted anteriorly with References a squint hook, clamped for 10 s, and excised with Vannas 1 Scott MH, Richard JM, Farris BK. -
The National Economic Burden of Rare Disease Study February 2021
Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc. -
Neonatal Dermatology Review
NEONATAL Advanced Desert DERMATOLOGY Dermatology Jennifer Peterson Kevin Svancara Jonathan Bellew DISCLOSURES No relevant financial relationships to disclose Off-label use of acitretin in ichthyoses will be discussed PHYSIOLOGIC Vernix caseosa . Creamy biofilm . Present at birth . Opsonizing, antibacterial, antifungal, antiparasitic activity Cutis marmorata . Reticular, blanchable vascular mottling on extremities > trunk/face . Response to cold . Disappears on re-warming . Associations (if persistent) . Down syndrome . Trisomy 18 . Cornelia de Lange syndrome PHYSIOLOGIC Milia . Hard palate – Bohn’s nodules . Oral mucosa – Epstein pearls . Associations . Bazex-Dupre-Christol syndrome (XLD) . BCCs, follicular atrophoderma, hypohidrosis, hypotrichosis . Rombo syndrome . BCCs, vermiculate atrophoderma, trichoepitheliomas . Oro-facial-digital syndrome (type 1, XLD) . Basal cell nevus (Gorlin) syndrome . Brooke-Spiegler syndrome . Pachyonychia congenita type II (Jackson-Lawler) . Atrichia with papular lesions . Down syndrome . Secondary . Porphyria cutanea tarda . Epidermolysis bullosa TRANSIENT, NON-INFECTIOUS Transient neonatal pustular melanosis . Birth . Pustules hyperpigmented macules with collarette of scale . Resolve within 4 weeks . Neutrophils Erythema toxicum neonatorum . Full term . 24-48 hours . Erythematous macules, papules, pustules, wheals . Eosinophils Neonatal acne (neonatal cephalic pustulosis) . First 30 days . Malassezia globosa & sympoidalis overgrowth TRANSIENT, NON-INFECTIOUS Miliaria . First weeks . Eccrine -
National Study of Microphthalmia, Anophthalmia, and Coloboma (MAC
16 ORIGINAL ARTICLE J Med Genet: first published as 10.1136/jmg.39.1.16 on 1 January 2002. Downloaded from National study of microphthalmia, anophthalmia, and coloboma (MAC) in Scotland: investigation of genetic aetiology D Morrison, D FitzPatrick, I Hanson, K Williamson, V van Heyningen, B Fleck, I Jones, J Chalmers, H Campbell ............................................................................................................................. J Med Genet 2002;39:16–22 We report an epidemiological and genetic study attempting complete ascertainment of subjects with microphthalmia, anophthalmia, and coloboma (MAC) born in Scotland during a 16 year period beginning on 1 January 1981. A total of 198 cases were confirmed giving a minimum live birth preva- lence of 19 per 100 000. One hundred and twenty-two MAC cases (61.6%) from 115 different fami- See end of article for lies were clinically examined and detailed pregnancy, medical, and family histories obtained. A authors’ affiliations simple, rational, and apparently robust classification of the eye phenotype was developed based on ....................... the presence or absence of a defect in closure of the optic (choroidal) fissure. A total of 85/122 Correspondence to: (69.7%) of cases had optic fissure closure defects (OFCD), 12/122 (9.8%) had non-OFCD, and Dr D FitzPatrick, MRC 25/122 (20.5%) had defects that were unclassifiable owing to the severity of the corneal or anterior Human Genetics Unit, chamber abnormality. Segregation analysis assuming single and multiple incomplete ascertainment, Western General Hospital, respectively, returned a sib recurrence risk of 6% and 10% in the whole group and 8.1% and 13.3% Edinburgh EH4 2XU, UK; in the OFCD subgroup. -
Guide to Policy & Practice Questions
OREGON BOARD OF CHIROPRACTIC EXAMINERS GUIDE TO POLICY & PRACTICE QUESTIONS 530 Center St NE, suite 620 Salem, OR 97301 (503) 378-5816 [email protected] Updated/Adopted: 9/17/2020 TABLE OF CONTENTS SECTION I ............................................................................................................................................................................................... 6 DEVICES, PROCEDURES, AND SUBSTANCES ............................................................................................................................... 6 DEVICES ................................................................................................................................................................ 6 BAX 3000 AND SIMILAR DEVICES................................................................................................................................................ 6 BIOPTRON LIGHT THERAPY ........................................................................................................................................................ 6 CPAP MACHINE, ORDERING ....................................................................................................................................................... 6 CTD MARK I MULTI-TORSION TRACTION DEVICE................................................................................................................... 6 DYNATRON 2000 ........................................................................................................................................................................... -
Treatment of Congenital Ptosis
13 Review Article Page 1 of 13 Treatment of congenital ptosis Vladimir Kratky1,2^ 1Department of Ophthalmology, Queen’s University, Kingston, Canada; 21st Medical Faculty, Charles University, Prague, Czech Republic Correspondence to: Vladimir Kratky, BSc, MD, FRCSC, DABO. Associate Professor of Ophthalmology, Director of Ophthalmic Plastic and Orbital Surgery, Oculoplastics Fellowship Director, Queen’s University, Kingston, Canada; 1st Medical Faculty, Charles University, Prague, Czech Republic. Email: [email protected]. Abstract: Congenital ptosis is an abnormally low position of the upper eyelid, with respect to the visual axis in the primary gaze. It can be present at birth or manifest itself during the first year of life and can be bilateral or unilateral. Additionally, it may be an isolated finding or part of a constellation of signs of a specific syndrome or systemic associations. Depending on how much it interferes with the visual axis, it may be considered as a functional or a cosmetic condition. In childhood, functional ptosis can lead to deprivation amblyopia and astigmatism and needs to be treated. However, even mild ptosis with normal vision can lead to psychosocial problems and correction is also advised, albeit on a less urgent basis. Although, patching and glasses can be prescribed to treat the amblyopia, the mainstay of management is surgical. There are several types of surgical procedure available depending on the severity and etiology of the droopy eyelid. The first part of this paper will review the different categories of congenital ptosis, including more common associated syndromes. The latter part will briefly cover the different surgical approaches, with emphasis on how to choose the correct condition. -
Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original Articles
Journal of Medical Genetics April 1992 Vol 29 No4 Contents Original articles Beckwith-Wiedemann syndrome: a demonstration of the mechanisms responsible for the excess J Med Genet: first published as on 1 April 1992. Downloaded from of transmitting females C Moutou, C Junien, / Henry, C Bonai-Pellig 217 Evidence for paternal imprinting in familial Beckwith-Wiedemann syndrome D Viljoen, R Ramesar 221 Sex reversal in a child with a 46,X,Yp+ karyotype: support for the existence of a gene(s), located in distal Xp, involved in testis formation T Ogata, J R Hawkins, A Taylor, N Matsuo, J-1 Hata, P N Goodfellow 226 Highly polymorphic Xbol RFLPs of the human 21 -hydroxylase genes among Chinese L Chen, X Pan, Y Shen, Z Chen, Y Zhang, R Chen 231 Screening of microdeletions of chromosome 20 in patients with Alagille syndrome C Desmaze, J F Deleuze, A M Dutrillaux, G Thomas, M Hadchouel, A Aurias 233 Confirmation of genetic linkage between atopic IgE responses and chromosome 1 1 ql 3 R P Young, P A Sharp, J R Lynch, J A Faux, G M Lathrop, W 0 C M Cookson, J M Hopkini 236 Age at onset and life table risks in genetic counselling for Huntington's disease P S Harper, R G Newcombe 239 Genetic and clinical studies in autosomal dominant polycystic kidney disease type 1 (ADPKD1) E Coto, S Aguado, J Alvarez, M J Menendez-DIas, C Lopez-Larrea 243 Short communication Evidence for linkage disequilibrium between D16S94 and the adult onset polycystic kidney disease (PKD1) gene S E Pound, A D Carothers, P M Pignatelli, A M Macnicol, M L Watson, A F Wright 247 Technical note A strategy for the rapid isolation of new PCR based DNA polymorphisms P R Hoban, M F Santibanez-Koref, J Heighway 249 http://jmg.bmj.com/ Case reports Campomelic dysplasia associated with a de novo 2q;1 7q reciprocal translocation I D Young, J M Zuccollo, E L Maltby, N J Broderick 251 A complex chromosome rearrangement with 10 breakpoints: tentative assignment of the locus for Williams syndrome to 4q33-q35.1 R Tupler, P Maraschio, A Gerardo, R Mainieri G Lanzi L Tiepolo 253 on September 26, 2021 by guest. -
Infantile Aphakia and Successful Fitting of Pediatric Contact Lenses; a Case Presentation Authors: Virji N, Patel A, Libassi D
Infantile aphakia and successful fitting of pediatric contact lenses; a case presentation Authors: Virji N, Patel A, Libassi D An eleven month old male presents with bilateral aphakia secondary to congenital cataracts. The patient is currently successfully wearing B&L Silsoft Pediatric contact lenses, with good prognosis for vision in both eyes. I. Case History -Patient demographics: African American male, DOB 8/18/2009 -Chief complaint: patient presents with bilateral aphakia secondary to bilateral congenital cataract extraction -Ocular, medical history: S/P CE with anterior vitrectomy OD 09/22/2009, followed by OS 09/29/09. (+) squinting, rubs eyes, light sensitivity -Medications: none -Other salient information: patient has been seen by SUNY Contact Lens clinic since 2 months old, 10/14/2009 II. Pertinent findings -Clinical: Keratometry readings 41.00/41.25 @ 005 OD, 38.50/41.00 @ 046 Axial length, immeasurable Horizontal corneal diameter 8mm OD/OS Fundus exam WNL OU -Others: surgical dates: successful CE OU, September 2009 III. Differential diagnosis -Primary/leading: Idiopathic -Others: Posterior lenticonus, persistent hyperplastic primary vitreous, anterior segment dysgenesis, and posterior pole tumors, trauma, intrauterine infection (rubella), maternal hypoglycemia, trisomy (eg, Down, Edward, and Patau syndromes), myotonic dystrophy, infectious diseases (eg, toxoplasmosis, rubella, cytomegalovirus, and herpes simplex [TORCH]), and prematurity. (5) IV. Diagnosis and discussion -Elaborate on the condition: Bilateral infantile cataracts are one of the major treatable causes of visual impairment in children. (2) Hubel and Weisel’s research on the critical period of visual development determined that if infantile cataracts are removed within the critical period and appropriate correction is worn, vision is greatly improved. -
Novel Anterior Segment Phenotypes Resulting from Forkhead Gene Alterations: Evidence for Cross-Species Conservation of Function
Novel Anterior Segment Phenotypes Resulting from Forkhead Gene Alterations: Evidence for Cross-Species Conservation of Function Ordan J. Lehmann,1 Stephen Tuft,2 Glen Brice,3 Richard Smith,4 Åsa Blixt,5 Rachel Bell,3 Bengt Johansson,6 Tim Jordan,1 Roger A. Hitchings,2 Peng T. Khaw,2 Simon W. M. John,4 Peter Carlsson,5 and Shomi S. Bhattacharya1 PURPOSE. Mutations in murine and human versions of an ances- cause it may affect the clinical management of certain trally related gene usually result in similar phenotypes. How- glaucoma subtypes and lead to excessive treatment. The ever, interspecies differences exist, and in the case of two FOXC1 and Foxe3 data, taken together with the novel ocular forkhead transcription factor genes (FOXC1 and FOXC2), phenotypes of FOXC2 mutations, highlight the remarkable these differences include corneal or anterior segment pheno- cross-species conservation of function among forkhead genes. types, respectively. This study was undertaken to determine (Invest Ophthalmol Vis Sci. 2003;44:2627–2633) DOI:10.1167/ whether such discrepancies provide an opportunity for iden- iovs.02-0609 tifying novel human–murine ocular phenotypes. METHODS. Four pedigrees with early-onset glaucoma pheno- types secondary to segmental chromosomal duplications or ecognition that mutations in orthologous genes frequently deletions encompassing FOXC1 and 18 individuals from 9 Rcause similar phenotypes has allowed the field of compar- FOXC2 mutation pedigrees underwent detailed ocular pheno- ative genetics to contribute to the understanding of human typing. Subsequently, mice with mutations in Foxc1 or a re- disease. As the human, murine, and Drosophila PAX6 mutants lated forkhead gene, Foxe3, were assessed for features of the (aniridia, Small eye, and eyeless) demonstrate, genotypic con- human phenotypes. -
Advances in Understanding the Genetics of Syndromes Involving Congenital Upper Limb Anomalies
Review Article Page 1 of 10 Advances in understanding the genetics of syndromes involving congenital upper limb anomalies Liying Sun1#, Yingzhao Huang2,3,4#, Sen Zhao2,3,4, Wenyao Zhong1, Mao Lin2,3,4, Yang Guo1, Yuehan Yin1, Nan Wu2,3,4, Zhihong Wu2,3,5, Wen Tian1 1Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China; 2Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Beijing 100730, China; 3Medical Research Center of Orthopedics, Chinese Academy of Medical Sciences, Beijing 100730, China; 4Department of Orthopedic Surgery, 5Department of Central Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China Contributions: (I) Conception and design: W Tian, N Wu, Z Wu, S Zhong; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: Y Huang; (V) Data analysis and interpretation: L Sun; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Wen Tian. Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China. Email: [email protected]. Abstract: Congenital upper limb anomalies (CULA) are a common birth defect and a significant portion of complicated syndromic anomalies have upper limb involvement. Mostly the mortality of babies with CULA can be attributed to associated anomalies. The cause of the majority of syndromic CULA was unknown until recently. Advances in genetic and genomic technologies have unraveled the genetic basis of many syndromes- associated CULA, while at the same time highlighting the extreme heterogeneity in CULA genetics. Discoveries regarding biological pathways and syndromic CULA provide insights into the limb development and bring a better understanding of the pathogenesis of CULA. -
Intraocular Lenses and Spectacle Correction
MEDICAL POLICY POLICY TITLE INTRAOCULAR LENSES, SPECTACLE CORRECTION AND IRIS PROSTHESIS POLICY NUMBER MP-6.058 Original Issue Date (Created): 6/2/2020 Most Recent Review Date (Revised): 6/9/2020 Effective Date: 2/1/2021 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY I. POLICY Intraocular Lens Implant (IOL) Initial IOL Implant A standard monofocal intraocular lens (IOL) implant is medically necessary when the eye’s natural lens is absent including the following: Following cataract extraction Trauma to the eye which has damaged the lens Congenital cataract Congenital aphakia Lens subluxation/displacement A standard monofocal intraocular lens (IOL) implant is medically necessary for anisometropia of 3 diopters or greater, and uncorrectable vision with the use of glasses or contact lenses. Premium intraocular lens implants including but not limited to the following are not medically necessary for any indication, including aphakia, because each is intended to reduce the need for reading glasses. Presbyopia correcting IOL (e.g., Array® Model SA40, ReZoom™, AcrySof® ReStor®, TECNIS® Multifocal IOL, Tecnis Symfony and Tecnis SymfonyToric, TRULIGN, Toric IO, Crystalens Aspheric Optic™) Astigmatism correcting IOL (e.g., AcrySof IQ Toric IOL (Alcon) and Tecnis Toric Aspheric IOL) Phakic IOL (e.g., ARTISAN®, STAAR Visian ICL™) Replacement IOLs MEDICAL POLICY POLICY TITLE INTRAOCULAR LENSES, SPECTACLE CORRECTION AND IRIS PROSTHESIS POLICY NUMBER